董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Teresa M. DeLuca | 女 | Independent Director | 60 | 10.38万美元 | 未持股 | 2026-01-01 |
| Blair E. Hendrix | -- | Chairman | -- | 未披露 | 未持股 | 2026-01-01 |
| J. Eric Evans | -- | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Laura L. Forese | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| T. Devin O'Reilly | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| John A. Deane | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Clifford G. Adlerz | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Andrew T. Kaplan | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Patricia A. Maryland | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Brent Turner | 男 | Independent Director | 59 | 7.50万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer B. Baldock | 女 | Executive Vice President, Chief Administrative Officer and Chief Development Officer | 54 | 64.01万美元 | 未持股 | 2026-01-01 |
| J. Eric Evans | -- | Director and Chief Executive Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Marissa A. Brittenham | -- | Executive Vice President and Chief Strategy Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Danielle Burkhalter | -- | Executive Vice President and Chief Human Resources Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| David T. Doherty | -- | Executive Vice President, Chief Financial Officer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Trenton William Webb | -- | President, American Group | -- | 未披露 | 未持股 | 2026-01-01 |
| Justin Oppenheimer | 男 | Chief Operating Officer and National Group President | 41 | 未披露 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Teresa M. DeLuca
-
Teresa M.DeLuca自2021年7月起担任公司董事。自2020年1月以来，德卢卡博士是纽约州纽约市的一名内科医师兼精神病学家，恢复了自己的执业。德卢卡博士曾于2018年1月至2019年12月担任哥伦比亚大学纽约生命科学风险基金的董事总经理。她作为董事总经理的职责包括领导一个由12个私人/公共机构组成的财团，冷泉港实验室，哥伦比亚大学，纽约市立大学，爱因斯坦，特殊外科医院，纪念斯隆·凯特琳癌症中心，西奈山，纽约大学，洛克菲勒大学，纽约州立大学下州医疗中心，石溪，威尔康奈尔大学，并为潜在的投资、合作、收购、商业化、许可和IPO提供尽职调查支持。在此之前，她于2014年8月至2017年12月担任纽约市西奈山伊坎医学院精神病学临床助理教授，并于2012年12月至2014年7月担任麦哲伦健康麦哲伦药房解决方案首席医疗官。在此之前，她曾担任Humana的药房健康解决方案高级副总裁，Walgreen Co.的临床销售解决方案副总裁兼国家医疗总监，个性化药物副总裁以及Medco的医疗政策和临床质量副总裁。在担任这些执行领导职务之前，DeLuca博士是葛兰素史克的高级医学科学家。德卢卡博士于2018年5月至2020年2月担任制药公司North Bud Farms，Inc.的董事（CSE代码:NBUD），并担任Surgery Partners, Inc.（纳斯达克代码:SGRY）的董事，该公司是手术设施和辅助服务的领先运营商，自2016年9月以来，目前还担任Surgery Partners, Inc.董事会的审计委员会和合规与道德委员会主席DeLuca博士在罗切斯特大学获得学士学位。德卢卡博士在德雷克塞尔大学获得工商管理硕士学位，在格林纳达圣乔治大学医学院获得医学博士学位，之后在托马斯·杰斐逊大学医学院实习。DeLuca博士大力倡导良好的董事会治理，2016年获得了卡内基梅隆大学网络安全证书，并继续在美国企业董事协会担任董事会领导研究员（硕士级别），并在2020年通过了NACD’；S“；董事认证”；考试。德卢卡博士还被任命为2020年董事，在董事和董事会年度报告中进行观察。
Teresa M. DeLuca,has served as a director of 180 Life Sciences Corp. Company since July 9, 2021. Dr. DeLuca is a physician executive and psychiatrist in New York, New York, resuming her own practice, since January 2020. Dr. DeLuca previously served as a Managing Director at Columbia University's NY Life Science Venture Fund from January 2018 to December 2019. Her responsibilities as Managing Director included leading a consortium of 12 private/public institutions (Cold Spring Harbor Laboratory, Columbia, CUNY, Einstein, Hospital for Special Surgery, Memorial Sloan Kettering Cancer Center, Mount Sinai, NYU, Rockefeller University, SUNY Downstate Medical Center, Stony Brook, Weil Cornell), and providing due diligence support for potential investments, partnerships, acquisitions, commercialization, licensing, and IPOs. Before that she served as Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City from August 2014 to December 2017 and as the Chief Medical Officer of Magellan Pharmacy Solutions at Magellan Health from December 2012 to July 2014. Prior to that, she served as SVP of Pharmacy Health Solutions at Humana, VP of Clinical Sales Solutions & National Medical Director at Walgreen Co., and VP of Personalized Medicine as well as VP of Medical Policy & Clinical Quality at Medco. Prior to taking on these executive leadership roles, Dr. DeLuca was a Senior Medical Scientist at GlaxoSmithKline. Dr. DeLuca served as a director at North Bud Farms, Inc., a pharmaceutical company from May 2018 to February 2020 (CSE:NBUD) and has served as a director of Surgery Partners, Inc. (NASDAQ:SGRY), a leading operator of surgical facilities and ancillary services, since September 2016, and also currently serves on the Audit Committee and Chair Compliance and Ethics Committee of the Board of Directors of Surgery Partners, Inc. In March 2022, Dr. DeLuca joined the Board of Directors of Rejuveron, a private Swiss drug discovery company and serves on the Audit Committee and Chair of Governance and Remuneration Committees of such company.Dr. DeLuca received a Bachelor's degree from the University of Rochester / LIU. Dr. DeLuca received her M.B.A. from Drexel University and her M.D. from St. Georges University School of Medicine, before undertaking her residency at Thomas Jefferson University Medical School. A strong advocate for good board governance, in 2016, Dr. DeLuca earned the Carnegie Mellon Cybersecurity certificate and in 2022 passed the Digital Directors Network Cyber Risk Masterclass examination. She continues to maintain good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow (Masters Level), and in 2020 Dr. DeLuca passed the NACD's "Directorship Certified" examination (NACD.DC). In addition, in 2022, Dr. DeLuca became a NACD "Subject Matter Expert" in examination development and a Board Advisory Faculty Member and also earned the American College of Corporate Directors (ACCD) "Advanced Professional Director" credential. Dr. DeLuca was also named "2020 Director to Watch" in the Directors & Board Annual Report and named "2022 Director of the Month" in Chief Executive Magazine. Dr. DeLuca is also the Co-Chair and Leadership Council Member for the international organization, Women Corporate Directors (WCD). - Teresa M.DeLuca自2021年7月起担任公司董事。自2020年1月以来，德卢卡博士是纽约州纽约市的一名内科医师兼精神病学家，恢复了自己的执业。德卢卡博士曾于2018年1月至2019年12月担任哥伦比亚大学纽约生命科学风险基金的董事总经理。她作为董事总经理的职责包括领导一个由12个私人/公共机构组成的财团，冷泉港实验室，哥伦比亚大学，纽约市立大学，爱因斯坦，特殊外科医院，纪念斯隆·凯特琳癌症中心，西奈山，纽约大学，洛克菲勒大学，纽约州立大学下州医疗中心，石溪，威尔康奈尔大学，并为潜在的投资、合作、收购、商业化、许可和IPO提供尽职调查支持。在此之前，她于2014年8月至2017年12月担任纽约市西奈山伊坎医学院精神病学临床助理教授，并于2012年12月至2014年7月担任麦哲伦健康麦哲伦药房解决方案首席医疗官。在此之前，她曾担任Humana的药房健康解决方案高级副总裁，Walgreen Co.的临床销售解决方案副总裁兼国家医疗总监，个性化药物副总裁以及Medco的医疗政策和临床质量副总裁。在担任这些执行领导职务之前，DeLuca博士是葛兰素史克的高级医学科学家。德卢卡博士于2018年5月至2020年2月担任制药公司North Bud Farms，Inc.的董事（CSE代码:NBUD），并担任Surgery Partners, Inc.（纳斯达克代码:SGRY）的董事，该公司是手术设施和辅助服务的领先运营商，自2016年9月以来，目前还担任Surgery Partners, Inc.董事会的审计委员会和合规与道德委员会主席DeLuca博士在罗切斯特大学获得学士学位。德卢卡博士在德雷克塞尔大学获得工商管理硕士学位，在格林纳达圣乔治大学医学院获得医学博士学位，之后在托马斯·杰斐逊大学医学院实习。DeLuca博士大力倡导良好的董事会治理，2016年获得了卡内基梅隆大学网络安全证书，并继续在美国企业董事协会担任董事会领导研究员（硕士级别），并在2020年通过了NACD’；S“；董事认证”；考试。德卢卡博士还被任命为2020年董事，在董事和董事会年度报告中进行观察。
- Teresa M. DeLuca,has served as a director of 180 Life Sciences Corp. Company since July 9, 2021. Dr. DeLuca is a physician executive and psychiatrist in New York, New York, resuming her own practice, since January 2020. Dr. DeLuca previously served as a Managing Director at Columbia University's NY Life Science Venture Fund from January 2018 to December 2019. Her responsibilities as Managing Director included leading a consortium of 12 private/public institutions (Cold Spring Harbor Laboratory, Columbia, CUNY, Einstein, Hospital for Special Surgery, Memorial Sloan Kettering Cancer Center, Mount Sinai, NYU, Rockefeller University, SUNY Downstate Medical Center, Stony Brook, Weil Cornell), and providing due diligence support for potential investments, partnerships, acquisitions, commercialization, licensing, and IPOs. Before that she served as Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City from August 2014 to December 2017 and as the Chief Medical Officer of Magellan Pharmacy Solutions at Magellan Health from December 2012 to July 2014. Prior to that, she served as SVP of Pharmacy Health Solutions at Humana, VP of Clinical Sales Solutions & National Medical Director at Walgreen Co., and VP of Personalized Medicine as well as VP of Medical Policy & Clinical Quality at Medco. Prior to taking on these executive leadership roles, Dr. DeLuca was a Senior Medical Scientist at GlaxoSmithKline. Dr. DeLuca served as a director at North Bud Farms, Inc., a pharmaceutical company from May 2018 to February 2020 (CSE:NBUD) and has served as a director of Surgery Partners, Inc. (NASDAQ:SGRY), a leading operator of surgical facilities and ancillary services, since September 2016, and also currently serves on the Audit Committee and Chair Compliance and Ethics Committee of the Board of Directors of Surgery Partners, Inc. In March 2022, Dr. DeLuca joined the Board of Directors of Rejuveron, a private Swiss drug discovery company and serves on the Audit Committee and Chair of Governance and Remuneration Committees of such company.Dr. DeLuca received a Bachelor's degree from the University of Rochester / LIU. Dr. DeLuca received her M.B.A. from Drexel University and her M.D. from St. Georges University School of Medicine, before undertaking her residency at Thomas Jefferson University Medical School. A strong advocate for good board governance, in 2016, Dr. DeLuca earned the Carnegie Mellon Cybersecurity certificate and in 2022 passed the Digital Directors Network Cyber Risk Masterclass examination. She continues to maintain good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow (Masters Level), and in 2020 Dr. DeLuca passed the NACD's "Directorship Certified" examination (NACD.DC). In addition, in 2022, Dr. DeLuca became a NACD "Subject Matter Expert" in examination development and a Board Advisory Faculty Member and also earned the American College of Corporate Directors (ACCD) "Advanced Professional Director" credential. Dr. DeLuca was also named "2020 Director to Watch" in the Directors & Board Annual Report and named "2022 Director of the Month" in Chief Executive Magazine. Dr. DeLuca is also the Co-Chair and Leadership Council Member for the international organization, Women Corporate Directors (WCD).
- Blair E. Hendrix
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- J. Eric Evans
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Laura L. Forese
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- T. Devin O'Reilly
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- John A. Deane
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Clifford G. Adlerz
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Andrew T. Kaplan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Patricia A. Maryland
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Brent Turner
-
Brent Turner，自2014年8月起担任董事。Turner先生目前是Summit BHC的首席执行官，Summit TERM0是一家领先的行为健康服务提供商。2011年至2019年，Turner先生担任Acadia Healthcare Company, Inc.总裁，该公司是美国领先的住院患者行为医疗保健提供商之一。他此前曾于2005年至2010年担任Psychiatric Solutions，Inc.的财务和行政执行副总裁，并于2003年至2005年担任Psychiatric Solutions的副总裁、财务主管和投资者关系。从1996年到2001年，Turner先生受雇于美国惩教公司，从1998年到2001年担任财务主管。Turner先生目前还担任Surgery Partners, Inc. NASDAQ：SRGY的董事会成员，此前曾担任美国行为健康协会董事会成员，并于2018年和2009年担任该协会主席。
Brent Turner has served as a director since August 2014. Mr. Turner is currently the Chief Executive Officer of Summit BHC, a leading provider of behavioral health services. From 2011 to 2019 Mr. Turner served as President of Acadia Healthcare Company, Inc., one of the country's leading providers of inpatient behavioral healthcare. He previously served as the Executive Vice President, Finance and Administration of Psychiatric Solutions, Inc. from 2005 to 2010 and as the Vice President, Treasurer, and Investor Relations of Psychiatric Solutions from 2003 to 2005. From 1996 until 2001 Mr. Turner was employed by Corrections Corporation of America, a private prison operator, serving as Treasurer from 1998 to 2001. Mr. Turner also currently serves on the Board of Directors of Surgery Partners, Inc. NASDAQ: SRGY and previously served on the Board of Trustees for the National Association for Behavioral Health and served as its Chairman in 2018 and 2009. - Brent Turner，自2014年8月起担任董事。Turner先生目前是Summit BHC的首席执行官，Summit TERM0是一家领先的行为健康服务提供商。2011年至2019年，Turner先生担任Acadia Healthcare Company, Inc.总裁，该公司是美国领先的住院患者行为医疗保健提供商之一。他此前曾于2005年至2010年担任Psychiatric Solutions，Inc.的财务和行政执行副总裁，并于2003年至2005年担任Psychiatric Solutions的副总裁、财务主管和投资者关系。从1996年到2001年，Turner先生受雇于美国惩教公司，从1998年到2001年担任财务主管。Turner先生目前还担任Surgery Partners, Inc. NASDAQ：SRGY的董事会成员，此前曾担任美国行为健康协会董事会成员，并于2018年和2009年担任该协会主席。
- Brent Turner has served as a director since August 2014. Mr. Turner is currently the Chief Executive Officer of Summit BHC, a leading provider of behavioral health services. From 2011 to 2019 Mr. Turner served as President of Acadia Healthcare Company, Inc., one of the country's leading providers of inpatient behavioral healthcare. He previously served as the Executive Vice President, Finance and Administration of Psychiatric Solutions, Inc. from 2005 to 2010 and as the Vice President, Treasurer, and Investor Relations of Psychiatric Solutions from 2003 to 2005. From 1996 until 2001 Mr. Turner was employed by Corrections Corporation of America, a private prison operator, serving as Treasurer from 1998 to 2001. Mr. Turner also currently serves on the Board of Directors of Surgery Partners, Inc. NASDAQ: SRGY and previously served on the Board of Trustees for the National Association for Behavioral Health and served as its Chairman in 2018 and 2009.
高管简历
中英对照 | 中文 | 英文- Jennifer B. Baldock
Jennifer B. Baldock，一直担任Surgery Center Holdings，Inc.的高级副总裁、秘书和总法律顾问；自2015年4月起担任Surgery Partners，Inc.的副总裁、秘书和总法律顾问。Baldock女士此前曾担任Symbion Holdings Corporation和Symbion，Inc.的总法律顾问和首席合规官。在2010年加入Symbion之前，她曾担任美国门诊服务和肾脏护理集团的助理总法律顾问。在此之前，Baldock女士在田纳西州纳什维尔的Waller Lansden Dortch和Davis从事法律执业，专注于公司法，重点是医疗保健并购。她也是一名注册会计师，非在职。Baldock女士拥有Lipscomb大学经济学和会计学文学士学位和阿拉巴马大学法学博士学位。
Jennifer B. Baldock has served as Senior Vice President, Secretary and General Counsel of Surgery Center Holdings, Inc. since acquisition of Symbion in November 2014 and as Vice President, Secretary and General Counsel of Surgery Partners, Inc. since April 2015. Ms. Baldock previously served as General Counsel and Chief Compliance Officer of Symbion Holdings Corporation and Symbion, Inc. Prior to joining Symbion in 2010 she served as Assistant General Counsel for both Ambulatory Services of America and Renal Care Group. Prior to that, Ms. Baldock practiced law with Waller Lansden Dortch and Davis in Nashville, Tennessee, concentrating in corporate law with an emphasis on healthcare mergers and acquisitions. She is also a Certified Public Accountant inactive. Ms. Baldock holds a Bachelor of Arts in Economics and Accounting from Lipscomb University and a Juris Doctor from the University of Alabama.- Jennifer B. Baldock，一直担任Surgery Center Holdings，Inc.的高级副总裁、秘书和总法律顾问；自2015年4月起担任Surgery Partners，Inc.的副总裁、秘书和总法律顾问。Baldock女士此前曾担任Symbion Holdings Corporation和Symbion，Inc.的总法律顾问和首席合规官。在2010年加入Symbion之前，她曾担任美国门诊服务和肾脏护理集团的助理总法律顾问。在此之前，Baldock女士在田纳西州纳什维尔的Waller Lansden Dortch和Davis从事法律执业，专注于公司法，重点是医疗保健并购。她也是一名注册会计师，非在职。Baldock女士拥有Lipscomb大学经济学和会计学文学士学位和阿拉巴马大学法学博士学位。
- Jennifer B. Baldock has served as Senior Vice President, Secretary and General Counsel of Surgery Center Holdings, Inc. since acquisition of Symbion in November 2014 and as Vice President, Secretary and General Counsel of Surgery Partners, Inc. since April 2015. Ms. Baldock previously served as General Counsel and Chief Compliance Officer of Symbion Holdings Corporation and Symbion, Inc. Prior to joining Symbion in 2010 she served as Assistant General Counsel for both Ambulatory Services of America and Renal Care Group. Prior to that, Ms. Baldock practiced law with Waller Lansden Dortch and Davis in Nashville, Tennessee, concentrating in corporate law with an emphasis on healthcare mergers and acquisitions. She is also a Certified Public Accountant inactive. Ms. Baldock holds a Bachelor of Arts in Economics and Accounting from Lipscomb University and a Juris Doctor from the University of Alabama.
- J. Eric Evans
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Marissa A. Brittenham
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Danielle Burkhalter
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- David T. Doherty
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Trenton William Webb
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Justin Oppenheimer
贾斯汀·奥本海默（Justin Oppenheimer）从特殊外科医院（HSS）加入Surgery Partners，过去十年他在该医院担任过各种领导职务，包括首席战略官和首席运营官。他还担任总部位于纽约的特许学校管理组织Urban Dove的董事会成员。他拥有普林斯顿大学政治经济学学士学位，哈佛商学院MBA学位。
Justin Oppenheimer,joins Surgery Partners from the Hospital for Special Surgery (HSS), where he spent the past decade in a variety of leadership roles, including Chief Strategy Officer and Chief Operating Officer. He also serves on the Board of Directors for Urban Dove, a New York-based charter school management organization. He holds a B.A. degree in political economy from Princeton University, and an MBA from Harvard Business School.- 贾斯汀·奥本海默（Justin Oppenheimer）从特殊外科医院（HSS）加入Surgery Partners，过去十年他在该医院担任过各种领导职务，包括首席战略官和首席运营官。他还担任总部位于纽约的特许学校管理组织Urban Dove的董事会成员。他拥有普林斯顿大学政治经济学学士学位，哈佛商学院MBA学位。
- Justin Oppenheimer,joins Surgery Partners from the Hospital for Special Surgery (HSS), where he spent the past decade in a variety of leadership roles, including Chief Strategy Officer and Chief Operating Officer. He also serves on the Board of Directors for Urban Dove, a New York-based charter school management organization. He holds a B.A. degree in political economy from Princeton University, and an MBA from Harvard Business School.